Labcorp has launched a new blood test designed to accelerate the diagnosis of Alzheimer’s disease, following recent FDA clearance of a similar test from Roche. The test, which measures levels of the protein p-tau217, aims to identify individuals in the early stages of Alzheimer’s, even before symptoms manifest.
The newly cleared test offers a less invasive alternative to traditional diagnostic methods like PET scans and spinal taps. According to a press release, Labcorp’s offering is the first FDA-cleared blood test specifically for Alzheimer’s disease. The test is intended for apply by healthcare professionals in evaluating individuals aged 55 and older experiencing cognitive impairment.
The development of this blood test represents a significant step forward in Alzheimer’s diagnosis, potentially allowing for earlier intervention and access to emerging treatments. Currently, a definitive Alzheimer’s diagnosis often requires lengthy and expensive procedures. The availability of a blood-based test could broaden access to diagnostic testing and expedite the process for many patients.
Roche’s test, which Labcorp will also carry, received FDA clearance earlier this month. The tests analyze blood samples for specific biomarkers associated with amyloid plaques and tau tangles – hallmarks of Alzheimer’s disease in the brain. While the tests can identify the presence of these biomarkers, interpretation of the results requires clinical expertise and should be considered alongside other diagnostic information.
Experts emphasize that a positive result on the blood test does not definitively confirm an Alzheimer’s diagnosis. Further evaluation, including neurological exams and cognitive assessments, is necessary to determine the underlying cause of cognitive impairment. Being Patient reported on the importance of understanding how to interpret these results, noting the need for a comprehensive clinical picture.
The launch of Labcorp’s test coincides with the company’s recent investment in neurology expertise, a move that has sparked debate among financial analysts regarding the company’s valuation, as noted by Yahoo Finance. The increased focus on neurological diagnostics signals Labcorp’s commitment to expanding its capabilities in this critical area of healthcare.
Research from Washington University School of Medicine suggests that these blood tests can even predict when a person will begin to experience Alzheimer’s symptoms, offering a “clock” to estimate the disease’s progression. This predictive capability could be invaluable for clinical trial recruitment and for individuals seeking to plan for their future care.
Labcorp has not yet announced pricing for the test, and questions remain regarding insurance coverage and accessibility. The company stated that it is working to ensure the test is widely available to healthcare providers and patients.
